MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  05/20 04:03:28 pm EDT
93.55 USD   +1.59%
05/20Merck's Keytruda Receives Positive EMA Panel Opinion as Adjuvant Therapy in Skin Cancer
MT
05/20Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
BU
05/20Merck Gets CHMP Backing for Expanded Keytruda Use in Melanoma
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 Technical AnalysisHistorical ChartNews ChartSector ChartComparison ChartReversed ChartRelative Strength Chart
Static chartExpert dynamic chartDynamic Chart 
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishBullish
Resistance94,8103103
Spread/Res.-1,3%-9,1%-9,1%
Spread/Supp.5,5%14%15%
Support88,782,081,4
Notations Surperformance© of Merck & Co., Inc.  Help  
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes